Carbiotix receives preliminary approval for European AXOS patent application

Feb 21, 2020, 15:00

Carbiotix (publ) ("Carbiotix") announces today that the company has received an "Intention to grant" from the European Patent Office (EPO) regarding its patent application for the AXOS ingredient. This marks an important milestone in securing Carbiotix competitive position for further commercialisation.

Carbiotix received confirmation from EPO of an intention to grant the company's European Patent Application no. 16786855.3, titled: Preparation comprising Arabinoxylo-Oligosaccharides, transferred back to Carbiotix during 2019. This will be Carbiotix first patent granted in Europe and represents an important patent to protect the company's prebiotic ingredient containing AXOS.  
Kristofer Cook, CEO for Carbiotix, comments

"The granting of this patent represents a key milestone in securing our competitive position in the European market and provides further confidence as we move ahead with the commercialisation of our corn fiber extract prebiotic ingredient containing AXOS. The global market for prebiotic ingredients, valued at close to 5 billion Euros (1), is by far the largest vertical we are targeting and is where we are bringing to the table close to 10 years of research and development work."  
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company's contact person set out below on 21 February 2020. 
Forward-looking statements  

This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. 

For further information:
Carbiotix AB
Kristofer Cook, CEO
Tel: 0708-796580

Carbiotix AB (CRBX) ( is a biotechnology company developing Microbiome Modulator Therapeutics that amplify the production of key metabolites for the treatment of different metabolic and chronic diseases. The company's therapeutics are based on a propriety AXOS soluble fiber, isolated bacterial strains, and innovative formulations, supported by cost effective gut health testing services used to regularly diagnose and monitor gut health, as well as dose therapeutics. 

Go Back